NCT00621296已完成2 期
Phase II Study of MP-424 in Patients With (Genotype 1b) Hepatitis C
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration
研究概览
简要总结
The purpose of this study is to assess the efficacy and safety after administration of MP-424 to patients with chronic hepatitis C.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients diagnosed with genotype 1b chronic hepatitis C
- •Patients naive to the concomitant medications with interferon
排除标准
- •Patients diagnosed with decompensated cirrhosis
- •Patients diagnosed with positive HBs antigen in the test
研究组 & 干预措施
MP-424
Experimental
干预措施: MP-424 (Telaprevir) (Drug)
结局指标
主要结局
Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration
时间窗: 24 Weeks After Completion of Drug Administration (dosing period is 24 Weeks) or drug withdrawal. The subjects were assessed at 24 weeks following the last dose of study drug.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based TherapyHepatitis CNCT00781274Tanabe Pharma Corporation32
已完成
3 期
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based TherapyChronic Hepatitis CNCT00780910Tanabe Pharma Corporation109
已完成
3 期
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis CHepatitis CNCT00780416Tanabe Pharma Corporation189
已完成
3 期
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CChronic Hepatitis C (CHC)NCT01753557Tanabe Pharma Corporation54
已完成
2 期
Clinical Trial in Subjects With Mild to Moderate Acne VulgarisAcne VulgarisNCT02832063AOBiome LLC372